David Fabrizio

15.8k total citations
88 papers, 2.9k citations indexed

About

David Fabrizio is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Fabrizio has authored 88 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 60 papers in Cancer Research and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Fabrizio's work include Cancer Genomics and Diagnostics (60 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Treatments and Mutations (33 papers). David Fabrizio is often cited by papers focused on Cancer Genomics and Diagnostics (60 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Treatments and Mutations (33 papers). David Fabrizio collaborates with scholars based in United States, United Kingdom and Switzerland. David Fabrizio's co-authors include Garrett M. Frampton, Siraj M. Ali, Jeffrey S. Ross, Alexa B. Schrock, Vincent A. Miller, Samuel J. Klempner, Kyle Gowen, Philip J. Stephens, Razelle Kurzrock and Aaron M. Goodman and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

David Fabrizio

83 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Fabrizio United States	26	1.9k	1.0k	927	666	504	88	2.9k
Marta Salido Spain	27	1.3k 0.7×	758 0.7×	683 0.7×	709 1.1×	594 1.2×	111	2.5k
W. Michael Korn United States	32	2.1k 1.1×	769 0.7×	906 1.0×	1.2k 1.8×	654 1.3×	197	3.4k
Adrian G. Sacher Canada	29	1.7k 0.9×	2.0k 1.9×	1.0k 1.1×	809 1.2×	267 0.5×	153	3.1k
Iacopo Petrini Italy	27	1.0k 0.5×	723 0.7×	688 0.7×	884 1.3×	280 0.6×	91	2.5k
Sherri Z. Millis United States	25	1.1k 0.6×	852 0.8×	421 0.5×	772 1.2×	360 0.7×	93	2.3k
Petros Nikolinakos United States	20	1.5k 0.8×	986 1.0×	869 0.9×	628 0.9×	338 0.7×	51	2.4k
Ryosuke Okamura Japan	24	1.3k 0.7×	789 0.8×	864 0.9×	557 0.8×	404 0.8×	86	2.2k
Chao Zhao China	34	2.3k 1.2×	2.0k 1.9×	1.0k 1.1×	1.1k 1.7×	216 0.4×	132	3.8k
Alison M. Schram United States	25	1.1k 0.6×	862 0.8×	783 0.8×	1.1k 1.6×	349 0.7×	100	2.9k
Ming‐Tseh Lin United States	30	1.2k 0.6×	853 0.8×	736 0.8×	897 1.3×	614 1.2×	76	3.3k

Countries citing papers authored by David Fabrizio

Since Specialization

Citations

This map shows the geographic impact of David Fabrizio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Fabrizio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Fabrizio more than expected).

Fields of papers citing papers by David Fabrizio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Fabrizio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Fabrizio. The network helps show where David Fabrizio may publish in the future.

Co-authorship network of co-authors of David Fabrizio

This figure shows the co-authorship network connecting the top 25 collaborators of David Fabrizio. A scholar is included among the top collaborators of David Fabrizio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Fabrizio. David Fabrizio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Madison, Russell W., Zoe J. Assaf, Alexander D. Fine, et al.. (2025). Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. JTO Clinical and Research Reports. 6(9). 100829–100829. 1 indexed citations

Zariffa, Névine, Katherine K. Nishimura, Yu Deng, et al.. (2025). Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy. Journal for ImmunoTherapy of Cancer. 13(9). e012454–e012454.

Keenan, Bridget P., Mahesh Yadav, George Ansstas, et al.. (2025). Intratumoral heterogeneity and immunotherapy resistance: clinical implications. Annals of Oncology. 37(3). 314–328. 1 indexed citations

Sweeney, Christopher J., Chang Xu, Jie He, et al.. (2024). Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 30(18). 4115–4122. 7 indexed citations

Moore, Jay A., Russell W. Madison, Justin Y. Newberg, et al.. (2023). Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response. JCO Precision Oncology. 7(7). e2300093–e2300093. 13 indexed citations

Sweeney, Christopher, Ryon P. Graf, David Fabrizio, et al.. (2023). Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.. Journal of Clinical Oncology. 41(6_suppl). LBA249–LBA249. 1 indexed citations

Ebot, Ericka M., Daniel Duncan, Khaled Tolba, et al.. (2022). Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. npj Precision Oncology. 6(1). 44–44. 15 indexed citations

Riviere, Paul, Aaron M. Goodman, Ryosuke Okamura, et al.. (2020). High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Molecular Cancer Therapeutics. 19(10). 2139–2145. 53 indexed citations

Klempner, Samuel J., David Fabrizio, Shalmali Bane, et al.. (2019). Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. The Oncologist. 25(1). e147–e159. 243 indexed citations

10.

Ross, Jeffrey S., Marwan Fakih, Siraj M. Ali, et al.. (2018). Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 124(7). 1358–1373. 149 indexed citations

11.

Johnson, Douglas B., Zachary R. Chalmers, Garrett M. Frampton, et al.. (2017). BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell & Melanoma Research. 31(3). 432–436. 28 indexed citations

12.

Fabrizio, David, Christine M. Malboeuf, Daniel S. Lieber, et al.. (2017). Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST). Annals of Oncology. 28. v27–v27. 14 indexed citations

13.

Lee, Hwajeong, Sanaz Ainechi, Laurie M. Gay, et al.. (2017). General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. Human Pathology. 70. 84–91. 20 indexed citations

14.

Ross, Jeffrey S., Laurie M. Gay, Jo‐Anne Vergilio, et al.. (2017). Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Annals of Oncology. 28(10). 2539–2546. 82 indexed citations

15.

Schrock, Alexa B., David Fabrizio, Yuxia He, et al.. (2017). Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs). Annals of Oncology. 28. v415–v415. 11 indexed citations

16.

Ross, Jeffrey S., Haiying Cheng, Román Pérez-Soler, et al.. (2017). MA04.09 RICTOR Amplification in Non-Small Cell Lung Cancer: An Emerging Therapy Target. Journal of Thoracic Oncology. 12(1). S362–S362. 1 indexed citations

17.

Hartmaier, Ryan J., Jehad Charo, David Fabrizio, et al.. (2017). Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9(1). 16–16. 42 indexed citations

18.

Dagogo‐Jack, Ibiayi, David Fabrizio, Jochen K. Lennerz, et al.. (2017). Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(10). e155–e157. 7 indexed citations

19.

Bailey, Michael, Alexa B. Schrock, Samuel J. Klempner, et al.. (2016). Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor. Annals of Oncology. 27. vi493–vi493. 2 indexed citations

20.

Frampton, Garrett M., et al.. (2016). Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes. Annals of Oncology. 27. vi15–vi15. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact